List of Excipients in Branded Drug CARAC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	CARAC	fluorouracil	0187-5200	CARBOMER HOMOPOLYMER TYPE C
Bausch Health US LLC	CARAC	fluorouracil	0187-5200	DIMETHICONE
Bausch Health US LLC	CARAC	fluorouracil	0187-5200	GLYCERIN
Bausch Health US LLC	CARAC	fluorouracil	0187-5200	METHYL GLUCETH-20

Last updated: August 9, 2026

ecutive summary: Carac is a 0.5% fluorouracil topical cream for actinic keratoses. Its commercial value is driven by formulation execution rather than active-ingredient exclusivity. The core opportunity is a low-irritation, cosmetically acceptable generic or differentiated fluorouracil cream that matches Carac's performance while improving preservative profile, spreadability, packaging, adherence, or tolerability. The main technical barriers are semisolid equivalence, fluorouracil stability, preservative control, manufacturing scale-up, and FDA evidence requirements for topical products.

Carac Fluorouracil Cream: Excipient Strategy, Patent Position, and Commercial Opportunities

What is Carac and how does its formulation work?

Carac is a prescription cream containing 0.5% fluorouracil, also known as 5-fluorouracil or 5-FU. It is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp in adults.[1]

Carac uses a conventional oil-in-water cream architecture. The formulation combines:

• Fluorouracil as the active pharmaceutical ingredient
• Carbomer 1342 as a rheology and structure-building polymer
• Dimethicone as a skin-conditioning and barrier-supporting excipient
• Glycerin as a humectant
• Propylene glycol as a solvent and humectant
• Stearic acid and glyceryl stearate as emollient and emulsifying components
• Sodium hydroxide for neutralization and pH adjustment
• Methylparaben as a preservative
• Purified water as the continuous aqueous phase

The precise inactive-ingredient composition should be taken from the current FDA-approved labeling and product specification. The published Carac label identifies these excipient classes and establishes the reference formulation for generic development.[1]

Why the excipient system matters

Fluorouracil is a small, polar antimetabolite that must be distributed uniformly throughout a semisolid vehicle. The excipient system affects:

1. Drug content uniformity across the tube.
2. Fluorouracil release from the cream.
3. Skin permeation and local exposure.
4. Physical stability during storage.
5. Patient-perceived texture and spreadability.
6. Irritation caused by the active drug and the vehicle.
7. Preservative effectiveness and microbial control.

For a topical generic, excipients are not interchangeable on a purely qualitative basis. Changes in polymer grade, neutralization, emulsifier ratio, preservative system, pH, particle size, or manufacturing shear can alter drug release and clinical performance.

What excipients are used in Carac 0.5% cream?

The reference formulation uses a balanced emulsion system rather than a simple aqueous gel. The principal formulation functions are summarized below.

Excipient or excipient class	Likely formulation function	Commercial relevance
Carbomer 1342	Viscosity, suspension support, cream structure	Polymer grade and neutralization affect release and sensory properties
Dimethicone	Emolliency, slip, barrier conditioning	Can improve skin feel and reduce perceived dryness
Glycerin	Humectancy	Supports moisturization but can affect tackiness
Propylene glycol	Solvent, humectant, penetration modifier	May improve drug distribution but can contribute to irritation
Stearic acid	Emollient and oil-phase structurant	Influences consistency and phase behavior
Glyceryl stearate	Emulsifier and emollient	Supports emulsion stability and cream texture
Sodium hydroxide	Carbomer neutralization and pH control	Excess or insufficient neutralization changes viscosity and release
Methylparaben	Antimicrobial preservation	Creates an opportunity for preservative-free differentiation
Purified water	Aqueous vehicle	Water quality and microbial control are critical

The central excipient design issue is the interaction among carbomer neutralization, fatty-acid structuring, emulsifier concentration, water activity, and fluorouracil solubility. A formulation that is physically stable but releases fluorouracil too slowly may fail comparative performance testing. A formulation that releases the drug rapidly may produce more irritation without improving clinical value.

What patents protect Carac and when does Carac lose exclusivity?

Carac's active ingredient, fluorouracil, is a long-established generic drug. The commercial exclusivity period for the original active ingredient has expired. The relevant competitive question is whether any unexpired formulation, method-of-use, or listed regulatory exclusivity remains enforceable.

The FDA label identifies Carac as an approved fluorouracil cream, but labeling alone does not establish an active patent estate. Orange Book patent listings and FDA exclusivity records are the controlling sources for current regulatory protection.[1,2]

Protection category	Carac position
Active-ingredient patent	Expired; fluorouracil is an established generic compound
Original product exclusivity	Expired
Formulation patent risk	Low based on the age and conventional nature of the product, subject to current Orange Book review
Method-of-use patent risk	Limited for the approved actinic-keratosis indication, subject to current listings
Regulatory exclusivity	No current orphan or new chemical entity exclusivity
Generic pathway	ANDA-based development is the principal route
Biosimilar risk	Not applicable; Carac is a small-molecule topical drug

Are Paragraph IV challenges relevant to Carac?

Paragraph IV litigation is relevant only if an applicant challenges an unexpired Orange Book-listed patent. For an old fluorouracil cream, the principal risk is not a blocking patent but the possibility of residual product-specific listings or later-issued formulation claims.

A generic applicant may pursue one of four approaches:

1. Paragraph III certification if a listed patent remains and the applicant waits for expiration.
2. Paragraph IV certification if the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.
3. Section viii carve-out for an unapproved method of use, where permitted.
4. A standard ANDA without a patent challenge if no relevant unexpired patents are listed.

The commercial value of a Paragraph IV strategy would depend on actual Orange Book listings, patent claim scope, litigation history, and the number of competing ANDAs. For Carac, formulation differentiation and manufacturing reliability are likely to matter more than patent litigation.

What formulation patents could protect a next-generation Carac product?

A new product could seek protection around a defined formulation, delivery system, manufacturing process, or combination of excipients. Broad claims covering "fluorouracil cream" would face substantial validity risk because fluorouracil topical formulations are well established. Stronger claims would require measurable technical distinctions.

Potential patentable formulation areas

Low-irritation vehicle

A formulation could target equivalent fluorouracil exposure with reduced burning, erythema, dryness, or treatment discontinuation. A credible patent position would need comparative data against Carac or another reference product.

Potential claim elements include:

• Specific pH range
• Defined carbomer concentration
• Controlled propylene glycol level
• Alternative emulsifier system
• Reduced surfactant content
• Specific oil-phase composition
• Preservative-free packaging
• Quantified release or permeation profile

Preservative-free formulation

Methylparaben is part of the reference excipient system. A preservative-free product could use a single-dose container, airless pump, sterile manufacturing, or a validated low-bioburden multidose package.

The commercial advantage would be strongest for patients with sensitive or reactive skin. The development cost would be higher because packaging, microbial limits, in-use stability, and preservative challenge testing would need to support the product design.

Improved cosmetic properties

Many patients discontinue topical fluorouracil because of irritation and poor cosmetic acceptability. A product with faster absorption, lower tack, improved spreadability, or reduced residue could compete even without clinical superiority.

Patent claims could focus on:

• A defined droplet-size distribution
• A specific viscosity range
• Low-residue emulsion structure
• Non-greasy silicone-containing vehicle
• Improved wash-off characteristics
• Controlled evaporation or occlusion

Alternative delivery systems

Opportunities include:

• Foams
• Gels
• Emulgels
• Metered-dose pumps
• Unit-dose sachets
• Film-forming systems
• Hydrogel patches
• Combination products with keratolytic or anti-inflammatory agents

These products would not necessarily be substitutable through a conventional ANDA. A new dosage form or delivery system may require a 505(b)(2) application or a different regulatory strategy, depending on the formulation and clinical claims.[3]

How should a generic manufacturer design the Carac excipient strategy?

The lowest-risk strategy is to reproduce the reference product's critical quality attributes while minimizing unnecessary excipient changes.

Recommended development priorities

Development priority	Objective	Key tests
Drug uniformity	Ensure consistent fluorouracil distribution	Assay, content uniformity, tube sampling
Rheology	Match application and release behavior	Viscosity curve, yield stress, thixotropy
In vitro release	Establish equivalence to reference	IVRT under FDA-recommended conditions
Physical stability	Prevent separation, crystallization, or viscosity drift	Accelerated and long-term stability
Chemical stability	Control fluorouracil degradation	Stability-indicating HPLC
Microbial quality	Maintain product safety	Microbial limits and preservative effectiveness
Skin compatibility	Reduce unnecessary vehicle irritation	In vitro screening and clinical tolerability
Packaging compatibility	Preserve product quality through shelf life	Extractables, leachables, sorption, tube compatibility

The manufacturer should treat polymer grade, neutralization endpoint, mixing order, temperature profile, homogenization energy, and filling conditions as critical process variables. Small changes in these parameters can change the microstructure of the cream.

Is Q1/Q2 sameness enough?

No. Qualitative and quantitative sameness can simplify development, but it does not eliminate the need to demonstrate product performance. FDA's topical dermatological guidance emphasizes pharmaceutical equivalence, quality, and appropriate comparative performance testing. For semisolid products, in vitro release testing is a central development tool, but the required evidence depends on the product-specific guidance and regulatory pathway.[3,4]

A manufacturer should avoid assuming that a Q1/Q2 formulation will automatically be therapeutically equivalent. Differences in excipient grade, particle size, process conditions, or packaging can affect topical delivery even when the ingredient list matches.

What commercial opportunities exist for Carac alternatives?

The market has several practical openings.

1. Low-cost generic fluorouracil cream

This is the simplest opportunity. The product can compete through:

• Reliable supply
• Lower acquisition cost
• Large-tube economics
• Pharmacy channel coverage
• Contract manufacturing efficiency

Price competition will be intense because fluorouracil is generic and multiple suppliers can serve the category.

2. Premium low-irritation product

A differentiated product could command a higher price if it demonstrates better tolerability or adherence. The evidence burden is greater. Claims should rely on controlled comparative data rather than cosmetic positioning alone.

A meaningful product concept would combine:

• A less irritating vehicle
• Improved application feel
• Clear dosing instructions
• Patient support materials
• Packaging that reduces product waste

3. Preservative-free product

A preservative-free cream or emulgel could target patients with contact sensitivity or compromised skin barriers. The strongest commercial positioning would use single-dose or airless packaging to solve the microbial-control problem rather than simply removing methylparaben.

4. Metered-dose delivery

A pump can improve dose consistency and reduce contamination from repeated finger contact. It may also support a more precise treatment regimen for field therapy. The tradeoff is higher packaging cost and possible regulatory complexity if the product is not otherwise equivalent to the reference cream.

5. Combination therapy

Fluorouracil could be paired with ingredients intended to improve field treatment, reduce inflammation, or address coexisting photodamage. Combination products face formulation and clinical-development challenges because the sponsor must establish compatibility, stability, dosing rationale, and benefit-risk.

6. International and emerging-market supply

Fluorouracil topical products are used across major markets. Opportunities may exist in countries where branded or reliable generic supply is limited. The commercial strategy would depend on local registration requirements, reference-product rules, trademark restrictions, and national reimbursement systems.

How does Carac compare with other fluorouracil products?

Carac is differentiated primarily by concentration and formulation, not by a proprietary active ingredient.

Product type	Fluorouracil concentration	Main commercial distinction
Carac cream	0.5%	Reference low-concentration cream for actinic keratoses
Conventional fluorouracil cream	Commonly 5%	Higher-strength topical treatment with greater local reaction burden
Fluorouracil solution	Product-dependent	Different application and drying characteristics
Fluorouracil plus alternative vehicle	Product-dependent	Possible differentiation through delivery and tolerability
Non-fluorouracil field therapies	Not applicable	Compete through different mechanisms, regimens, and tolerability

The closest competitive products are generic 0.5% fluorouracil creams. Higher-strength 5% products are clinically and commercially related but are not direct formulation substitutes.

What is the FDA regulatory status and Orange Book position?

Carac is an FDA-approved prescription topical product for actinic keratoses.[1] The FDA Orange Book provides the authoritative record for approved products, therapeutic-equivalence evaluations, listed patents, and regulatory exclusivity.[2]

For a prospective entrant, the regulatory assessment should focus on:

• The current Carac reference listed drug status
• Available product-specific guidance
• Therapeutic-equivalence requirements
• Listed patents and certifications
• Approved dosage form and strength
• Stability and manufacturing expectations for semisolid products
• Whether a formulation change requires an ANDA or 505(b)(2) pathway

Carac does not create biosimilar risk because fluorouracil is a synthetic small molecule, not a biologic. Manufacturing barriers are technical rather than biologic. The most important barriers are validated emulsion manufacture, analytical comparability, microbial control, and reproducible tube filling.

How strong is the patent estate for a Carac successor?

The patent estate is likely weak for a conventional copy and potentially stronger for a clinically differentiated formulation.

Product strategy	Patent strength potential	Commercial risk
Exact generic cream	Low	High price competition
Preservative-free version	Moderate if technically specific	Packaging and microbial-control cost
Low-irritation formulation	Moderate to high if supported by comparative data	Clinical and patent-validity burden
Metered-dose delivery	Moderate	Device and regulatory complexity
New dosage form	Moderate to high	May require 505(b)(2) development
Combination product	Potentially high	Clinical, stability, and market-access risk

A defensible patent position would require more than a new excipient name. It should connect a defined composition or device configuration to a measurable performance advantage, such as improved stability, release, dose uniformity, or tolerability.

What generic launch scenarios exist for Carac?

Immediate commodity launch

A manufacturer launches a conventional 0.5% cream after completing ANDA development. This approach offers the shortest path to market but exposes the product to rapid price erosion.

Differentiated generic launch

The manufacturer maintains reference-like performance while improving packaging, texture, or preservative profile. This may support better contracting and pharmacy acceptance without requiring a new therapeutic claim.

505(b)(2) lifecycle product

A sponsor develops a new delivery system or combination product. This path can create stronger differentiation but requires more extensive clinical, CMC, and regulatory work.

Geographic licensing

A regional pharmaceutical company could license formulation technology, manufacturing know-how, or local commercialization rights. The most valuable assets would be a robust comparative-performance package, scalable manufacturing process, and freedom-to-operate analysis covering formulation and packaging claims.

Key Takeaways

• Carac is a 0.5% fluorouracil cream for actinic keratoses.
• Its commercial opportunity is formulation-driven because fluorouracil has long been generic.
• The main excipient system includes carbomer, dimethicone, glycerin, propylene glycol, stearic acid, glyceryl stearate, sodium hydroxide, methylparaben, and purified water.
• The strongest development opportunities are low-irritation vehicles, preservative-free packaging, metered dosing, improved cosmetic properties, and alternative delivery systems.
• A conventional generic is likely to face price competition rather than a significant active-ingredient patent barrier.
• Formulation patents require specific compositions linked to measurable performance improvements.
• Biosimilar risk does not apply.
• The principal technical barriers are semisolid equivalence, fluorouracil stability, rheology control, microbial preservation, and manufacturing reproducibility.
• FDA Orange Book listings and current product-specific guidance control the final patent and regulatory assessment.

FAQs about Carac excipient and commercial strategy

Can propylene glycol be removed from a Carac generic?

Yes, but removing propylene glycol may change fluorouracil solubility, release, skin permeation, viscosity, and irritation. The replacement vehicle would require comparative formulation and performance testing.

Is a preservative-free Carac cream commercially viable?

Yes. A preservative-free product could target sensitive-skin patients, but it would need packaging and microbiological controls that prevent contamination during storage and use.

Can a new carbomer grade create patent protection?

Possibly, but the patent position would be weak if the only change is substitution of one commercially available carbomer for another. Stronger protection would require a defined composition and demonstrated technical effect.

Would a fluorouracil foam compete directly with Carac?

It could compete for the same actinic-keratosis treatment market, but a foam may require a different regulatory pathway and would not necessarily be therapeutically substitutable with Carac.

What is the most attractive commercial position for a Carac successor?

A low-irritation, cosmetically acceptable, preservative-free or metered-dose product has greater differentiation potential than an undifferentiated low-cost cream. The premium strategy requires comparative tolerability and performance data.

References

1. U.S. Food and Drug Administration. (n.d.). Carac (fluorouracil) cream, 0.5% prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2022). Product-specific guidance for generic drug development: Fluorouracil topical cream, 0.5%. FDA.

4. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical dermatological drug products submitted in ANDAs. FDA.